Life-changing

enzyme products

Our

Mission

At Oxidien™, we are dedicated to bringing life-changing products to patients in need. We create best-in-class enzyme-based pharmaceuticals. Using innovative research, open-minded conviction, and passionate diligence Oxidien™ is committed to advancing the standard of care. The name Oxidien™ stems from the dietary culprit (oxalate) and the patient indications we serve: “Ox” for oxalate, “idi” for idiopathic and “en” for enteric.

2° Hyperoxaluria

Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications. There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3.
  • IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones 1, 4, 5 .
  • EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.

Products

OX-1

OX-1 is a novel oxalate decarboxylase (OxDC) enzyme developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. OX-1 demonstrates stability in a wide pH range including very acidic environments; thus, can effectively degrade oxalate in the gastrointestinal tract, in particular the stomach.
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Utilizing Orally Administered Oxalate Decarboxylase (OxDC) To Reduce Urinary Oxalate
In Vitro And In Vivo Safety Evaluation of Ox-1

AA-1

AA-1 (also known as A0) is an oxalate decarboxylase (OxDC) enzyme originating from a fungal source. AA-1 has the potential to degrade oxalate throughout the complete gastrointestinal tract due to its extremely wide pH activity profile with activity in neutral and basic pH range.
Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate, an abstract and poster featuring research partner, Captozyme, and their A0 research.

Team

 Helena Cowley

Helena Cowley

MS, MBA

Chief Executive Officer
Paul Hassie

Paul Hassie

CPA

Chief Financial Officer
 Ira W. Klimberg

Ira W. Klimberg

MD

Chief Medical Officer
 Sabrina Buzzerd

Sabrina Buzzerd

BSBA, CCRP, CCRA

Director of Clinical Research
Loren Miller

Loren Miller

PhD

Regulatory Affairs
Jiayi Sun

Jiayi Sun

PhD

Scientist

Meet Us Here

For details on what we are up to and where we are, please check out our Events and Presentations page.

Oxidien Pharmaceuticals, LLC

747 SW 2nd Avenue, IMB 57 Gainesville, FL 32601

Phone